MedTrace Logo

Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF

NCT02644447 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-01-13

No results posted yet for this study

Summary

Cellular therapies are rapidly progressing fields and have shown immense promise in the treatment of damaged ovarian function. The purpose of this study is to determine safety and efficacy of intra-ovarian injection of allogeneic HUC-MSCs with injectable collagen scaffold in women with Premature Ovarian Failure (POF) and to study the preliminary efficacy of HUC-MSCs with injectable collagen scaffold injection on ovarian function improvement.

Conditions

  • Premature Ovarian Failure

Interventions

BIOLOGICAL

HUC-MSCs Transplantation

The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.

BIOLOGICAL

HUC-MSCs with Injectable Collagen Scaffold Transplantation

The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Jianwu Dai, Ph.D · Chinese Academy of Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02644447 on ClinicalTrials.gov